Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer

Abstract

BackgroundUnderstanding socio-demographic inequalities in stage at diagnosis can inform priorities for cancer control.Patients and methodsWe analysed data on the stage at diagnosis of East of England patients diagnosed with any of 10 common cancers, 2006–2010. Stage information was available on 88 657 of 98 942 tumours (89.6%).ResultsSubstantial socio-demographic inequalities in advanced stage at diagnosis (i.e. stage III/IV) existed for seven cancers, but their magnitude and direction varied greatly by cancer: advanced stage at diagnosis was more likely for older patients with melanoma but less likely for older patients with lung cancer [odds ratios for 75–79 versus 65–69 1.60 (1.38–1.86) and 0.83 (0.77–0.89), respectively]. Deprived patients were more likely to be diagnosed in advanced stage for melanoma, prostate, endometrial and (female) breast cancer: odds ratios (most versus least deprived quintile) from 2.24 (1.66–3.03) for melanoma to 1.31 (1.15–1.49) for breast cancer. In England, elimination of socio-demographic inequalities in stage at diagnosis could decrease the number of patients with cancer diagnosed in advanced stage by ∼5600 annually.ConclusionsThere are substantial socio-demographic inequalities in stage at diagnosis for most cancers. Earlier detection interventions and policies can be targeted on patients at higher risk of advanced stage diagnosis.

The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project

“…Range of the optimal utilization proportion for cancer site according to the stage at diagnosis distribution. from the four countries included is wide enough [20][21][22], with the possible exception of countries with no information available about incidence and survival [23]. Among the most important tumours from a radiotherapy perspective, that is, those with a high incidence and a high percentage of patients with evidence-based indications for radiotherapy (i.e.…”

Do stage of disease, comorbidity or access to treatment explain socioeconomic differences in survival after ovarian cancer? – A cohort study among Danish women diagnosed 2005–2010

“…Having no health insurance or being underinsured [30,31] and older age were, however, related to advanced stage [29,30]. Also a tendency was found that advanced stage was more frequent among women from deprived than affluent areas in Scotland [32], but this was not found in East of England [33]. Social inequity in diagnostic stage points to explanations such as delay by patients in seeking health care, differences in patient's symptom awareness, or doctor's delay in referring patients to specialists care.…”

Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs

“…From this, it is estimated that 41.8% (12 179) were stage I [30]; 86% (10 473) received adjuvant radiotherapy [31]; and 50% of the stage I ER/HER2 unknown (5236) were of luminal A subtype [14]. The UK PRIME trial that randomised patients age !…”